OneCell Diagnostics has Secured $16 Million in Series A Round Funding

Cancer diagnostics startup OneCell Diagnostics has raised $16 million in Series A funding, led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.

Funding Utilisation

The funds will be used to expand into the U.S. market with OncoIndx Alfa, a next-gen liquid biopsy test that detects circulating tumor cells.

Founded in 2021, OneCell uses advanced sequencing, bioinformatics, AI/ML, and data analytics to develop biomarkers for cancer.

Mohan Uttarwar, CEO and co-founder at OneCell Diagnostics said, “We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,". 

OncoIndx Alfa provides advanced biomarkers that help improve cancer diagnosis and treatment, including monitoring treatment responses, tracking disease progression, and detecting recurrence.

Read also - Yubi Group partnership with India Factoring

OneCell partners with All India Institute of Medical Science in New Delhi, Tata Memorial Centre, and leading academic institutions like Harvard Medical School and Stanford University.

The company has launched several products and tested its cell biopsy technology on nearly 10,000 patients in India.

About OneCell Diagnostics

OneCell Diagnostics focuses on developing innovative liquid biopsy tests using circulating tumor cells (CTC) for precision oncology, clinical cancer care, and early-stage clinical trials for biotech and pharma companies.

Startup Success Stories: Discover inspiring tales of startups overcoming challenges and achieving success.

Funding Startup News: Stay updated with the latest news and trends in startup funding and investment.

Startup Insights: Dive into in-depth analyses of various industries and market trends to make informed business decisions.